Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03428958
Other study ID # NuTide:302
Secondary ID 2017-002062-53
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date October 16, 2018
Est. completion date March 21, 2024

Study information

Verified date March 2024
Source NuCana plc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a three-part study of NUC-3373 administered by intravenous (IV) infusion across two administration schedules, either as monotherapy or as part of various combinations with agents commonly used to treat CRC (leucovorin, oxaliplatin, irinotecan, bevacizumab, cetuximab and panitumumab). The primary objective is to identify a recommended dose and schedule for NUC-3373 when combined with these agents.


Recruitment information / eligibility

Status Completed
Enrollment 107
Est. completion date March 21, 2024
Est. primary completion date March 19, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: All patients 1. Provision of written informed consent 2. Have histological confirmation of CRC with evidence of locally advanced/unresectable or metastatic disease 3. Age =18 years 4. Life expectancy of =12 weeks 5. ECOG Performance status 0 or 1 6. Measurable disease as defined by RECIST v1.1 7. Known RAS and BRAF status. Patients with wild-type KRAS tumours who are to be enrolled to a cohort that does not contain an EGFR pathway inhibitor (Arms 2a, 2b, 2c, 2d, 3a, 3b, 3c, 3d and 3e) must have received prior treatment with an EGFR inhibitor, unless this was not standard of care according to relevant region-specific treatment recommendations. Patients with BRAF V600E mutant tumours should have received prior treatment with encorafenib in combination with an EGFR inhibitor, unless this was not standard of care according to relevant region-specific treatment recommendations 8. Adequate bone marrow function as defined by: ANC =1.5×10^9/L, platelet count =100×10^9/L (with no evidence of bleeding), and haemoglobin =9 g/dL 9. Adequate liver function as defined by serum total bilirubin =1.5×ULN, AST and ALT =2.5×ULN (or =5×ULN if liver metastases present) 10. Adequate renal function assessed as serum creatinine <1.5×ULN or glomerular filtration rate =50 mL/min. This criterion does not apply to Arm 1d. 11. Serum albumin =3 g/dL 12. For the cohort in which the patient will participate, there are no contra-indications to receiving the approved partner combination drugs 13. Ability to comply with protocol requirements 14. Female patients of child-bearing potential must have a negative serum pregnancy test within 7 days prior to the first study drug administration. This criterion does not apply to patients who have had a previous hysterectomy or bilateral oophorectomy. Male patients and female patients of child-bearing potential must agree to practice true abstinence or to use two highly effective forms of contraception, one of which must be a barrier method. 15. Patients must have been advised to take measures to avoid or minimise exposure to UV light for the duration of study participation and for a period of 4 weeks following the last dose of study medication 16. Male patients receiving oxaliplatin must have been offered advice on and/or sought counselling for conservation of sperm prior to the first dose of study medication >3rd-line patients 1. Received at least two prior lines of therapy for locally advanced or metastatic CRC, including one fluoropyrimidine plus oxaliplatin and one fluoropyrimidine plus irinotecan containing regimen. Previous treatment with SoC regimens in combination with molecular targeted therapies is permitted and patients who received FOLFOXIRI-based regimens in 1st-/2nd-line settings may be included. 2. Patients due to receive NUFOX should be suitable for re-challenge with an oxaliplatin-based regimen 3. Patients due to receive NUFIRI should be suitable for re-challenge with an irinotecan-based therapy 2nd-/3rd-line patients 1. Received at least one but no more than two prior lines of fluoropyrimide-containing therapy in combination with oxaliplatin and/or irinotecan for locally advanced or metastatic CRC. Previous treatment with SoC regimens in combination with molecular targeted therapies is permitted and patients who received FOLFOXIRI-based regimens in 1st-/2nd-line settings may be included. 3rd-line patients enrolled to Arms 2c and 2d must have received prior bevacizumab treatment, unless ineligible or unless bevacizumab was not standard of care according to relevant region-specific treatment recommendations 2. Patients in Part 2 due to receive NUFOX should be suitable for re-challenge with an oxaliplatin-based regimen 3. Patients in Part 2 due to receive NUFIRI should be suitable for re-challenge with an irinotecan-based regimen Combination chemotherapy ineligible patients 1. May have received one prior fluoropyrimidine-containing regimen for locally advanced or metastatic CRC 2. Ineligible to receive combination therapy for locally advanced or metastatic CRC 3. Creatinine clearance >30mL/min Rapid progressors 1. Received no more than two prior lines of fluoropyrimidine-containing therapy in combination with oxaliplatin and/or irinotecan for locally advanced or metastatic CRC. Previous treatment with SoC regimens in combination with molecular targeted therapies is permitted and patients who received FOLFOXIRI-based regimens in 1st-/2nd-line settings may be included. 2. Have had tumour progression =3 months of starting the last fluoropyrimide-containing regimen 3. Patients due to receive NUFOX should be suitable for re-challenge with an oxaliplatin-based regimen 4. Patients due to receive NUFIRI should be suitable for re-challenge with an irinotecan-based regimen 2nd-line patients 1. Received one prior line of fluoropyrimidine-containing therapy in combination with oxaliplatin and/or irinotecan for locally advanced or metastatic CRC. Previous treatment with SoC regimens in combination with molecular targeted therapies is permitted and patients who received triplet chemotherapy based regimens is allowed. Maintenance patients 1. Received at least 12 weeks of 1st-line SoC therapy for locally advanced or metastatic CRC and achieved at least stable disease 2. Eligible for maintenance therapy Exclusion Criteria: All patients 1. Prior history of hypersensitivity or current contra-indications to 5-FU or capecitabine 2. Prior history of hypersensitivity or current contra-indications to any of the combination agents required for the study arm to which the patient is assigned 3. History of allergic reactions attributed to the components of the NUC-3373 drug product formulation 4. Symptomatic CNS or leptomeningeal metastases 5. Symptomatic ascites, ascites currently requiring drainage procedures or ascites requiring drainage over the prior 3 months 6. Chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy [e.g. for bone pain]), immunotherapy or exposure to another investigational agent within 28 days (or five times half-life for a biological or molecular targeted agent or three times the half-life for an immunotherapy agent) of first receipt of study drug 7. Residual toxicities from prior chemotherapy or radiotherapy, which have not regressed to Grade =1 severity (CTCAE v5.0) except for alopecia. In cohorts not containing oxaliplatin, residual Grade 2 neuropathy is allowed. 8. History of another malignancy diagnosed within the past 5 years, with the exception of adequately treated non-melanoma skin cancer curatively treated carcinoma in situ of the cervix, surgically excised or potentially curatively treated ductal carcinoma in situ of the breast, or low grade prostate cancer or patients after prostatectomy not requiring treatment. Patients with previous invasive cancers are eligible if treatment was completed more than 3 years prior to initiating the current study treatment and there is no evidence of recurrence. 9. Presence of active bacterial or viral infection (including SARS-CoV-2, Herpes Zoster or chicken pox), known HIV positive or known active hepatitis B or C 10. Presence of any uncontrolled concurrent serious illness, medical condition or other medical history, including laboratory results, which, in the Investigator's opinion, would be likely to interfere with their participation in the study, or with the interpretation of the results 11. Any condition (e.g. known or suspected poor compliance, psychological instability, geographical location) that, in the judgment of the Investigator, may affect the patient's ability to sign the informed consent and undergo study procedures 12. Currently pregnant, lactating or breastfeeding 13. QTc interval >450 milliseconds for males and >470 milliseconds for females 14. Required concomitant use of drugs known to prolong QT/QTc interval 15. Required concomitant use of strong CYP3A4 inducers or strong CYP3A4 inhibitors, or use of strong CYP3A4 inducers within 2 weeks of first receipt of study drug or use of strong CYP3A4 inhibitors within 1 week of first receipt of study drug 16. For patients receiving irinotecan: Use of strong UGT1A1 inhibitors within 1 week of first receipt of study drug 17. Has received a live vaccination within four weeks of first planned dose of study medication 18. Known DPD or TYMP mutations associated with toxicity to fluoropyrimidines 19. Use of warfarin and other types of long acting anti-coagulants is prohibited within 4 weeks of the first dose of study treatment Patients receiving bevacizumab 1. Patients with a history of haemoptysis (=1/2 tsp of red blood) 2. Wound healing complications or surgery within 28 days of starting bevacizumab 3. Severe chronic wounds, ulcers or bone fracture 4. Arterial thromboembolic events or haemorrhage within 6 months prior to study entry (except for tumour bleeding surgically treated by tumour resection) 5. Bleeding diatheses or coagulopathy 6. Receiving full-dose anti-coagulation treatment 7. Uncontrolled hypertension 8. Clinically significant coronary heart disease or myocardial infarction within the last 12 months or high risk of uncontrolled arrhythmia 9. Severe proteinuria 10. Acute or subacute ileus, chronic inflammatory bowel disease or chronic diarrhoea 11. Any contraindications present in the bevacizumab Prescribing Information Patients receiving cetuximab or panitumumab 1. Clinically significant coronary heart disease or myocardial infarction within the last 12 months or high risk of uncontrolled arrhythmia 2. Acute or subacute ileus, chronic inflammatory bowel disease or chronic diarrhoea 3. Hypomagnesaemia or hypokalaemia not controlled by oral therapy 4. Any contraindications present in the cetuximab or panitumumab Prescribing Information

Study Design


Intervention

Drug:
NUC-3373 + leucovorin
NUC-3373 + leucovorin
NUC-3373
NUC-3373
NUFOX
NUC-3373 + oxaliplatin
NUFOX + VEGF pathway inhibitor
NUC-3373 + oxaliplatin + bevacizumab
NUFOX + EGFR inhibitor
NUC-3373 + oxaliplatin + cetuximab/panitumumab
NUFIRI
NUC-3373 + irinotecan
NUFIRI + VEGF pathway inhibitor
NUC-3373 + irinotecan + bevacizumab
NUFIRI + EGFR inhibitor
NUC-3373 + irinotecan + cetuximab/panitumumab
NUC-3373 + bevacizumab
NUC-3373 + bevacizumab

Locations

Country Name City State
France Hopital Franco-Britannique Levallois-Perret
United Kingdom The Beatson West of Scotland Cancer Centre Glasgow
United Kingdom University College London Hospitals NHS Foundation Trust London
United Kingdom University of Oxford Oxford
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Dana Farber Cancer Institute Boston Massachusetts
United States Duke University Medical Center Durham North Carolina
United States Vanderbilt University Nashville Tennessee
United States Seattle Cancer Center Seattle Washington
United States Compass Oncology Vancouver Washington

Sponsors (1)

Lead Sponsor Collaborator
NuCana plc

Countries where clinical trial is conducted

United States,  France,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients reporting treatment-emergent adverse events (TEAEs) Treatment-emergent adverse events will be assessed and graded by CTCAE v5.0 Assessed from baseline to 30 days after last dose of study drug
Primary Number of patients with treatment-emergent clinically significant changes in laboratory parameters, ECG changes, or changes in physical examinations Each will be assessed and graded by CTCAE v5.0 Assessed from baseline to 30 days after last dose of study drug
Secondary Tolerability of NUC-3373 in each combination cohort measured by dose intensity in Cycle 1 Dose intensity will be measured by the actual dose received as compared to the projected dose to be administered in Cycle 1 Assessed from baseline to 30 days after last dose of study drug
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A